Dr. Christopher Flowers, M.D., Department of Lymphoma – Myeloma, Division of Cancer Medicine and chair of Lymphoma & Myeloma at The University of Texas MD Anderson Cancer Center and POLARIX clinical trial investigator, shares his perspectives on the recent FDA approval of Polivy (polatuzumab vedotin-piiq) in combination with R-CHP as a first-line treatment for adults with certain types of diffuse large B-cell lymphoma (DLBCL), an aggressive blood cancer and the most common form of non-Hodgkin’s lymphoma in the U.S. For more information please visit www.lymphoma.org or lls.org.
Dr. Flowers is a globally recognized leader in lymphoma clinical and population science research as well as a national leader in hematology and medical oncology.
He serves as an oncologist specializing in the treatment of lymphoma and professor at the MD Anderson Cancer Center at The University of Texas
He served as the co-senior author on POLARIX trial and has authored over 300 articles published in multiple top peer-reviewed journals.